Iberdomide is a medication being studied for its potential to help people with a type of blood cancer called multiple myeloma. It is being tested to see if it can help keep the cancer from coming back after patients have received a stem cell transplant. Iberdomide works by affecting the immune system and the cancer cells, aiming to slow down or stop the growth of the cancer.

Lenalidomide is another medication used in the study for patients with multiple myeloma. It is already used in treating this type of cancer and works by helping the immune system attack cancer cells and by stopping the cancer cells from growing. In this trial, it is being used as a comparison to see how well it works against iberdomide in preventing the return of cancer after a stem cell transplant.

Multiple Myeloma – Multiple Myeloma is a type of blood cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. It begins when a single plasma cell becomes abnormal and multiplies rapidly, leading to the accumulation of these abnormal cells in the bone marrow. As the disease progresses, it can cause bone pain, fractures, anemia, kidney dysfunction, and increased susceptibility to infections. The abnormal plasma cells produce an excess of a single type of antibody, which can be detected in the blood or urine. Over time, the disease can lead to damage in various organs and tissues, primarily due to the overproduction of these abnormal antibodies and the crowding out of normal blood cells.